PhosCo (ASX:PHO) banks A$1.1m EBRD grant with A$7.5m waiting behind the study

Option exercises add A$0.6m and a Q3 2026 study release becomes the trigger for institutional money

PhosCo (ASX:PHO) has tidied up its balance sheet at exactly the right moment. The company has banked a A$1.1m grant instalment from the European Bank for Reconstruction and Development (EBRD) and pulled in another A$0.6m from shareholders exercising options early during May and June.

Sitting on top of the A$5.7m it held at 31 March, the cash position now looks comfortable enough to carry the Gasaat Phosphate Project through to its next inflection point. That inflection point is the Updated Scoping Study, which management has guided for release in Q3 2026.

The more interesting line in today’s announcement is what happens AFTER the study lands. EBRD has agreed to put a further A$7.5m of equity into the company on exercise of its options, conditional on the Updated Scoping Study being released. That turns the next quarter into the moment a development-stage explorer becomes a properly funded feasibility-stage one.

Why the EBRD relationship matters more than the headline grant figure

Junior explorers usually raise capital one of two ways. They hit the market for a placement that dilutes existing holders, or they get strategic capital from a partner who has done its own diligence and decided the project is worth backing.

EBRD is firmly in the second category. The bank has already provided grant funding that paid for the KM definition drilling and the metallurgical breakthrough that simplified the flowsheet to single-stage flotation.

The skeptical read is that grants are easy money and tell you nothing about commercial viability. The constructive read is that EBRD does not commit A$7.5m of equity to projects it has not stress-tested.

The Q3 2026 Scoping Study is now the only catalyst that matters

Everything in the PhosCo story now funnels into the Updated Scoping Study. The KM resource at a 0.4 to 1 strip ratio, the SAB addition and the simpler flotation flowsheet all need to flow through to lower opex numbers than the 2022 study assumed.

We think the market is currently pricing PhosCo on the old 2022 economics plus a vague sense that things have improved. The Updated Scoping Study is where those improvements get put into numbers the market can actually value.

Our concern is timing. Resource-stage companies have a habit of slipping these dates by a quarter, and investors should not treat Q3 as guaranteed.

Option exercises are a small signal worth reading carefully

The A$0.6m from early option exercises is not material in dollar terms, but the behaviour is worth noting. Holders typically wait until the last possible moment to exercise, because doing so earlier converts optionality into cash outlay.

Eleven point two million options being exercised ahead of expiry suggests at least some holders expect the share price to move meaningfully before the original deadline. That is the kind of insider-adjacent signal worth filing away ahead of the study release.

The Investors Takeaway for PhosCo

PhosCo now has the cash to get to the Updated Scoping Study without going back to market. More importantly, it has a A$7.5m equity commitment from EBRD waiting on the other side, which materially de-risks the Gasaat Feasibility Study funding question.

The bull case rests on the study reflecting the simpler flowsheet, the KM strip ratio and the broader district-scale picture that has emerged since 2022. The bear case is that study delays or weaker economics deflate the catalyst window before the EBRD equity converts.

Investors can read our prior coverage of the DOH discovery and the broader Gasaat resource picture at stocksdownunder.